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FEBRUARY 2014
Zimbabwe has seen a substantial shift in the 
HIV landscape in the last decade, with prev-
alence among adults aged 15 and above 
decreasing from an estimated 24.3 percent 
of the population in 2001 to less than 15 
percent in 2012 (UNAIDS 2013). The reduc-
tion in the number of people living with HIV 
(PLHIV) has been attributed to scaling up 
both treatment and prevention (Hargrove et 
al. 2011). In particular, increased emphasis 
on behavioural interventions, such as con-
dom use and reduction of sexual partners 
has been credited with nearly halving the 
number of new infections annually between 
2001 and 2012 (Gregson et al. 2010; Halp-
erin et al. 2011). Yet, despite this progress, 
many people, especially women, are still at 
high risk and efforts to identify and imple-
ment additional HIV prevention options 
remain critical.
These developments have taken place 
against the backdrop of unprecedented 
socio-economic decline in Zimbabwe, which 
has significantly compromised the avail-
ability, use, and quality of health and social 
services. As a result, coverage of most basic 
health services has decreased, leading to 
stagnation or deterioration of some health 
indicators.
Despite the political and economic situation 
in Zimbabwe, clinical research is of the high-
est caliber, and Zimbabwe has participated 
in many large-scale HIV prevention trials, 
including safety and effectiveness studies 
of tenofovir gel and several other candidate 
microbicides. Topically applied microbicides 
are under development as a method women 
could use to reduce their risk of HIV and pos-
sibly other sexually transmitted infections. 
Tenofovir gel has been shown to reduce the 
risk of HIV acquisition by 39 percent in the 
CAPRISA 004 trial in South Africa,  the first 
candidate microbicide to show effectiveness 
in a clinical trial (Abdool Karim et al. 2010). 
The confirmatory FACTS 001 trial of tenofovir 
gel is now underway in South Africa, with 
results expected in 2014.
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Background on this Brief 
Given the urgent need for HIV prevention options for 
women, a number of projects are underway to prepare 
for introduction of tenofovir gel should it be shown ef-
fective. One of these is a toolkit developed by the Pop-
ulation Council to assist policymakers and programme 
managers in identifying the most strategic opportuni-
ties for introducing tenofovir gel. The toolkit includes 
three related components: a landscape analysis; a 
discussion guide for key opinion leader interviews; and 
a programme planning tool. The landscape analysis, 
summarised in this programme brief, includes a review 
of the epidemiologic context of the HIV epidemic along 
with a scan of key policies and programmes related 
to HIV and most relevant to tenofovir gel. It draws on 
a desk review of peer-reviewed and grey literature as 
well as interviews with key decision makers. The full re-
port and annexes are available at www.popcouncil.org.
HIV in Zimbabwe 
Zimbabwe, with an estimated population of 12.7 
million people, is among the countries in sub-Saharan 
Africa most affected by the HIV epidemic. In 2012, a 
total of 1.2 million adults and children were living with 
HIV and AIDS. This includes an estimated 14.7 percent 
of the population 15–49 years old, with an estimated 
69,000 new infections in 2012 
(UNAIDS 2013). HIV in Zimbabwe is 
characterised by variation among 
and within provinces at the local 
and district levels. Many HIV treat-
ment and prevention programmes 
have targeted these defined geo-
graphic areas, and such a focus 
may be appropriate for ultimate 
delivery of tenofovir gel. 
Zimbabwe has a generalised, 
heterosexually driven HIV epidemic; 
heterosexual transmission accounts 
for over 90 percent of HIV infec-
tions in the country (UNAIDS 2012). 
Vertical transmission, where HIV 
is passed from a mother to child 
during pregnancy, childbirth, and/or 
breastfeeding, is the second most 
common source of HIV in the country. Both modes of 
transmission remain pressing public health challenges 
despite considerable attention to address them. 
In fact, Zimbabwe is on track to achieve the Millennium 
Development Goal of halting and reversing the spread 
of HIV/AIDS by 2015 due both to high AIDS mortal-
ity rates and to changes in sexual behaviour. These 
behaviour changes, such as increased use of condoms 
in casual relationships and partner reduction, have 
resulted largely from personal experience with AIDS 
mortality (Gregson et al. 2010; Halperin et al. 2011). 
Although Zimbabwe is one of the few countries in the 
region to have experienced a substantial reduction in 
HIV prevalence, HIV/AIDS continues to be a significant 
contributor to the overall burden of disease. 
Women, Girls, and HIV 
HIV prevalence is higher among women than men 
across all age groups, except those 40–49 years old 
(see Figure 1). In particular, prevalence in some young-
er age groups is almost twice as high among women 
as among men (UNAIDS 2013). Sex with high-risk 
partners and multiple partners continues to be strong-
ly associated with risk of HIV infection among women. 
Young women’s risk is driven by a complex array of 
biological, social, economic and structural factors, in-
cluding gender-based violence and men’s alcohol use. 
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Figure 1  HIV prevalence by age and gender
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As in many other settings, gender-based violence is 
associated with HIV in Zimbabwe. The 2010–11 ZDHS 
(ZIMSTAT/ICF International 2012) found that sexual 
and physical violence occurred in intimate and other 
relationships across culture and class. Thirty percent 
of women aged 15–49 reported having experienced 
physical violence since the age of 15. The most com-
mon perpetrator was a current or former husband or 
partner. Married women who had experienced physical 
and/or sexual violence were significantly more likely 
to be HIV positive than those who had not experienced 
any physical or sexual violence (Nyamayemombe et al. 
2010).
Men’s alcohol use has also been correlated with in-
creasing women’s risk of HIV; consumption of alcohol 
is associated with men having higher numbers of 
sexual partners, and higher rates of HIV infection (Fras-
er et al. 2011). In Zimbabwe, research on the role of 
beer halls in the HIV epidemic shows that going to beer 
halls was associated with concurrent sexual partner-
ships (Lewis et al. 2005) and that men who reported 
having sex while drunk were more likely to report 
unprotected sex with casual partners and when paying 
for sex (Fraser et al. 2011).
Most at-risk Populations
Data on prevalence and incidence are scarce among 
those identified by UNAIDS as the most at-risk popula-
tions—men who have sex with men (MSM), sex work-
ers, and injecting drug users (IDUs). Little information 
is available about the overall HIV prevalence in these 
populations, and to date no systematic size estima-
tions have been conducted. Sex work and homosexu-
ality are both illegal in Zimbabwe, and this, combined 
with definitional and measurement problems, means 
that both are likely to be underreported. The lack of 
legal status and protections for sex workers and MSM 
presents obstacles to effective HIV prevention, treat-
ment, care and support in these populations. Despite 
these challenges, some groups focused on HIV preven-
tion have identified “hot spots” among these groups 
and provided services for sex workers and MSM, as 
well as IDUs. 
Reproductive Health Indicators
Contraceptive Prevalence 
According to the 2010–2011 Zimbabwe Demograph-
ic Health Survey (ZDHS), 59 percent of all married 
women surveyed reported using family planning, 
nearly all using a modern method. Oral contra-
ceptive pills were the most common method, used 
by 41 percent of women, while use of injectables, 
male and female condoms, implants and steriliza-
tion was less common (ZIMSTAT/ICF International 
2012). Given the relatively high overall use of family 
planning programmes, efforts to deliver tenofovir gel 
could build on this system, including the logistics 
for product storage and distribution of contraceptive 
commodities.
Sexually Transmitted Infections (STIs) 
HIV infection is clustered among people with a history 
of STIs, especially genital ulcer disease. According 
to the 2010–2011 ZDHS, 10 percent of women and 
seven percent of men had had an STI or STI symptoms 
in the year preceding the survey. Of those, 47 percent 
of women and 48 percent of men sought advice or 
treatment from a clinic, hospital, private doctor, or 
other health professionals (ZIMSTAT/ICF International 
2012). STI prevention is now part of HIV prevention 
programmes in Zimbabwe and is linked to other pro-
grammes including antenatal care (ANC), sexual and 
reproductive health, HIV testing and counselling (HTC), 
prevention of mother-to-child transmission (PMTCT), 
antiretroviral treatment (ART) and condom promotion 
(UNAIDS 2012). 
Maternal Health Care
The 2010–11 ZDHS shows that 90 percent of women 
who gave birth in the previous five years received ante-
natal care from a trained health professional for their 
last birth. The majority of women in Zimbabwe deliver 
in a health facility with a trained attendant; 65 percent 
of births were delivered in a health facility. 
A cohort study showed that HIV incidence was very 
high during the first nine months after childbirth 
(5.7/100 women-years-at-risk). Women who knew 
that their partners had other sexual partners were 
about four times more likely to acquire HIV (Munjoma 
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et al. 2010). These data suggest that the post-partum 
period may be a particularly important time to reach 
women with new HIV prevention technologies or strate-
gies, and that post-partum or infant care programmes 
might be considered as potential venues for pilot 
programmes. The relatively high proportion of births 
delivered in a health facility may provide an opportuni-
ty to encourage women to come for follow-up services, 
including making HIV prevention methods available.
Policy Environment
Zimbabwe’s policies, strategies and programmes 
have both anticipated and responded to established 
priorities and emerging approaches to HIV prevention. 
Zimbabwe’s national response to the HIV epidemic has 
been guided by the National Policy on HIV and AIDS, 
which was adopted in December 1999 through an act 
of Parliament. The current Zimbabwe National HIV and 
AIDS Strategic Plan (ZNASP) 2011–2015 is driven by 
the National AIDS Council (NAC), and its implementa-
tion is spearheaded by the Ministry of Health (MoH). It 
is supported by the National AIDS Trust Fund (NATF), a 
three percent levy on personal and corporate income. 
Its priorities are: 
 ● Prevention of new HIV infections in adults and chil-
dren, aiming to reduce the rate of annual infections 
by 50 percent by 2015; 
 ● Reduction of mortality among people living with HIV, 
aiming to reduce annual AIDS deaths by 38 percent 
by 2015.
Complementing and building on these overall policies 
are various sector-level policies, strategies and work-
plans, many of which emphasise the importance of 
prevention in Zimbabwe’s response to HIV. Specific 
guidelines covering the range of standard and emerg-
ing biomedical interventions are based on local evi-
dence as well as international standards. Zimbabwe is 
also increasingly looking at policies to address broader 
structural factors that drive HIV risk. For example, 
the US Centers for Disease Control and Prevention 
is assisting Zimbabwe to develop an alcohol policy, 
indicating recognition of the role that alcohol use 
plays in driving risky behavior and HIV incidence. This 
policy environment reflects the country’s commitment 
to fulfilling a number of international and regional 
obligations related to HIV, and a degree of openness to 
new prevention approaches even in the face of consid-
erable economic constraints. 
Despite significant political and economic uncertainty, 
Zimbabwe has relatively well-developed policy and 
regulatory environments, along with technical experts 
who have played pivotal roles in a number of trials of 
microbicides and other female-initiated prevention 
technologies. Zimbabwe’s commitment to and success 
with introducing and making available the female con-
dom is noteworthy (see below). This policy and scien-
tific expertise can be brought to bear on a thorough 
analysis of how tenofovir gel can address the specific 
prevention needs of the country. 
Regulatory Processes
Several entities will need to be involved in the regulato-
ry process in Zimbabwe, should tenofovir gel be proven 
efficacious. The Medicines Control Authority of Zimba-
bwe (MCAZ) is the key regulatory body responsible for 
product licensure, while the MoH oversees overall HIV 
prevention programmes. The National Medicines and 
Therapeutics Policy Advisory Committee (NMTPAC) has 
the mandate to advise the MoH on the introduction of 
new drugs into Zimbabwe. Ad hoc expert committees 
are convened to review data and make a recommen-
dation to NMTPAC as to whether or not a new drug 
should be introduced. Then the NMTPAC makes a rec-
ommendation to the MoH, which ultimately determines 
whether a drug will be made available in Zimbabwe. 
Licensure by MCAZ is an essential step before the MoH 
draws up guidelines for use and distribution. Given 
MCAZ’s central role in reviewing clinical trial data it 
may be useful to involve this group as soon as possible 
to speed the approval process in Zimbabwe. 
Programmes and Strategy 
The public health system in Zimbabwe has a number 
of programmes that could potentially serve as the set-
ting for introducing tenofovir gel. Some key elements of 
these programmes are summarised below. 
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Condoms 
Male condoms 
Zimbabwe has developed a strong infrastructure for 
condom distribution from the national to community 
levels, including social marketing initiatives. In 2008, 
95.5 million male condoms were distributed, although 
the current 2011–2015 strategic plan’s annual target 
of 150 million has not yet been met. Reported condom 
use is relatively high during high-risk sex (47 percent 
of females; 71 percent of males), but condom use with 
regular partners remains low (4 percent of females, 8 
percent of males) (Fraser et al. 2011).
Female condoms 
Female condom promotion and distribution is spear-
headed by the MoH, the Zimbabwe National Family 
Planning Council (ZNFPC) and Population Services 
International (PSI). Female condoms are sold through 
pharmacies and hair salons, as well as barber shops, 
sex worker networks, and support groups for PLHIV. Fe-
male condom distribution has been relatively success-
ful in Zimbabwe. For example, between 2004–2007 
Care brand female condom distribution increased 
by 150 percent and public sector distribution tripled 
(CHANGE 2009). Although delivery of tenofovir gel 
will be different, involving the formal health system to 
manage testing, monitoring and other issues, experi-
ence with the female condom can help inform how pro-
grammes in Zimbabwe and elsewhere can successfully 
reach women with a new female-initiated prevention 
technology. 
PMTCT
Provision of PMTCT services in Zimbabwe has contin-
ued to improve. In 2009, 56 percent of pregnant wom-
en who tested positive for HIV benefitted from antiret-
roviral (ARV) prophylaxis, although HIV testing reached 
only 46 percent of pregnant women (UNICEF 2010). 
At the end of 2009, 55 percent of ANC facilities were 
registered to offer comprehensive PMTCT services and 
the rest were providing a minimum package of PMTCT 
services. More efficacious treatment regimens for 
mothers were piloted and the PMTCT treatment guide-
lines were amended in 2010 (Ciaranello et al. 2011).
HIV Testing 
Overall testing availability and use is relatively high 
in Zimbabwe. HIV testing and counselling (HTC) has 
evolved to a nationwide programme of provider-initi-
ated testing and counselling (PICT). HTC services are 
provided through mobile outreach, workplace pro-
grammes, and family planning clinics. These services 
are also available at Level 1 health facilities, a large 
proportion of which offer PICT and voluntary coun-
selling and testing (VCT). The 2011 ZDHS reported 
generally uniform coverage rates (79–82 percent) of 
HIV testing among women across all age groups.  
With the advent of the WHO guidelines suggesting ini-
tiating treatment at a CD4 count of 350, the NAC has 
encouraged people to be re-tested so that they may be 
put on ARV treatment (NAC 2013). While data on  
re-testing is minimal, programme experience and esti-
mates suggest an increase in re-testing among people 
who have previously tested HIV negative. This has 
been attributed to increased access to ART medica-
tion. Further analysis of these clients and programmes 
may provide insights for structuring the testing and 
re-testing that will be needed for ARV-based prevention 
implementation. While it is possible that adding tenofo-
vir gel may create a burden for the already taxed HIV 
testing system, it would also give providers something 
to offer to women who test negative, and potentially 
attract women to HIV testing services. 
Financing 
Both domestic and international sources of support 
have funded Zimbabwe’s HIV and AIDS response. The 
Government of Zimbabwe’s main source of domestic 
funding is generated through the NATF. The Ministry 
of Finance channels these funds directly to the NAC. 
According to the UNAIDS 2012 country report, NATF 
contributed approximately US$5 million in 2009, 
US$20.5 million in 2010, and US$26.5 million in 2011 
towards HIV programmes. Approximately 50 percent of 
these funds were used for ARV procurement, and the 
remainder supported other HIV programmes, adminis-
tration and coordination (UNAIDS 2012). 
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International contributions for HIV and AIDS also 
increased sharply from approximately US$54 million in 
2009 to US$114 million in 2010, attributable in part 
to monies from Global Fund Round 8 Phase 1 funds 
(UNAIDS 2012). During this time, the proportion of 
total HIV/AIDS spending for prevention decreased from 
39 percent in 2006 to 22 percent in 2009, reflecting 
the shift of resources and programme emphasis to 
treatment roll-out. Of the 2009 expenditure for preven-
tion, over 40 percent was spent on PMTCT activities; 
about 17 percent on communication for social and 
behaviour change; and about 15 percent on VCT. 
Given that the challenging economic climate in Zim-
babwe will likely remain a significant barrier to govern-
ment financing for tenofovir gel introduction, external 
agencies will be needed to help support the cost of 
both programming and subsidizing product, at least 
initially. 
Looking Ahead
Zimbabwe can build on its policy and scientific capac-
ity to determine whether tenofovir gel offers added 
benefits relative to costs within the evolving context 
of prevention interventions, including relatively new 
approaches such as treatment as prevention, medical 
male circumcision and oral pre-exposure prophylaxis. 
If Zimbabwe determines that tenofovir gel would be a 
useful addition to its HIV prevention programme, pilot 
demonstration projects will be critical to determine the 
most strategic entry points for tenofovir gel introduc-
tion. These may include services for family planning, 
and HIV testing and re-testing, as well as programmes 
for post-partum women and sero-discordant couples. 
Such projects would assess the overall feasibility of 
introduction as well as identify ways to address specific 
operational issues. Zimbabwe’s momentum in reduc-
ing HIV, experience with new technologies and clinical 
trials, as well as its capacity for operations research, 
makes it a conducive setting to design and conduct 
such demonstration projects, and initial planning and 
protocol development can begin now. 
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